Ritu Salani

8.4k total citations · 3 hit papers
165 papers, 4.6k citations indexed

About

Ritu Salani is a scholar working on Reproductive Medicine, Obstetrics and Gynecology and Oncology. According to data from OpenAlex, Ritu Salani has authored 165 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 82 papers in Reproductive Medicine, 78 papers in Obstetrics and Gynecology and 52 papers in Oncology. Recurrent topics in Ritu Salani's work include Endometrial and Cervical Cancer Treatments (76 papers), Ovarian cancer diagnosis and treatment (74 papers) and Intraperitoneal and Appendiceal Malignancies (28 papers). Ritu Salani is often cited by papers focused on Endometrial and Cervical Cancer Treatments (76 papers), Ovarian cancer diagnosis and treatment (74 papers) and Intraperitoneal and Appendiceal Malignancies (28 papers). Ritu Salani collaborates with scholars based in United States, Taiwan and Canada. Ritu Salani's co-authors include Robert E. Bristow, Floor Backes, David E. Cohn, Deborah K. Armstrong, David M. O’Malley, Jeffrey M. Fowler, Larry J. Copeland, Robert Giuntoli, Christine H. Holschneider and Ie‐Ming Shih and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

In The Last Decade

Ritu Salani

157 papers receiving 4.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline

2016 295 citations Alexi A. Wright, Kari Bohlke et al. Journal of Clinical Oncology profile →
Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline

2016 274 citations Alexi A. Wright, Kari Bohlke et al. Gynecologic Oncology profile →
Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early-Stage Endometrial Cancer

2019 209 citations Marcus E. Randall, Virginia L. Filiaci et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Ritu Salani

Since Specialization

Citations

This map shows the geographic impact of Ritu Salani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ritu Salani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ritu Salani more than expected).

Fields of papers citing papers by Ritu Salani

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ritu Salani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ritu Salani. The network helps show where Ritu Salani may publish in the future.

Co-authorship network of co-authors of Ritu Salani

This figure shows the co-authorship network connecting the top 25 collaborators of Ritu Salani. A scholar is included among the top collaborators of Ritu Salani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ritu Salani. Ritu Salani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Changes in anthropometry, adiposity, and inflammation in Black and White women engaged in intentional weight loss 2024 ·Obesity ·Ashley S. Felix, Jennifer A. Sinnott, Bette J. Caan, Shannon L. Gillespie, (unknown), (unknown), Casey Cosgrove, (unknown), Sabrena Noria, Kristin Bixel, Ritu Salani, Christa Nagel, Laura Chambers, David E. Cohn, Adrian A. Suarez, Electra D. Paskett	1
2	Increase in uterine cancer incidence among Black patients in the United States: A United States Cancer Statistics Study of nearly 95,000 patients from 2001 to 2019 2024 ·Gynecologic Oncology ·(unknown), Cheng-I Liao, (unknown), C. A. Johnson, Ritu Salani, Daniel S. Kapp, John K. Chan	1
3	Racial/ethnic minority under-enrollment in gynecologic oncology: An analysis of over 350 clinical trials (017) 2023 ·Gynecologic Oncology ·Michael Richardson, Danika Barry, Jecca R. Steinberg, (unknown), (unknown), Brandon E. Turner, Christopher J. Magnani, Brannon T. Weeks, Anna Marie P. Young, (unknown), (unknown), (unknown), (unknown), Jill N. Anderson, (unknown), (unknown), Lynn M. Yee, Dario R. Roque, Ritu Salani	1
4	Cytochrome P450 inhibiting/inducing medication use among patients with advanced ovarian cancer who receive or are eligible for poly (ADP-ribose) polymerase inhibitors as first line maintenance therapy (2200) 2023 ·Gynecologic Oncology ·Dana M. Chase, B.J. Rimel, (unknown), Armen A. Ghazarian, Ella X. Du, (unknown), Jinlin Song, Amanda Golembesky, Jean Hurteau, Ritu Salani, Bradley J. Monk	1
5	Lunchbox trial: A randomized phase III trial of cisplatin and irradiation followed by carboplatin and paclitaxel versus sandwich therapy of carboplatin and paclitaxel followed by irradiation then carboplatin and paclitaxel for advanced endometrial carcinoma 2023 ·Gynecologic Oncology ·Joyce N. Barlin, (unknown), Ashar Ata, Béatrice Cormier, (unknown), Ritu Salani, Floor Backes, Kimberly Levinson, Leigh A. Cantrell, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Patrick Timmins	3
6	Implicit biases in healthcare: implications and future directions for gynecologic oncology 2022 ·American Journal of Obstetrics and Gynecology ·(unknown), Dana M. Chase, Ritu Salani, Heidi Hamann, Jeff Stone	3
7	Surgical Science–Simbionix Robotic Hysterectomy Simulator: Validating a New Tool 2022 ·Journal of Minimally Invasive Gynecology ·(unknown), (unknown), (unknown), (unknown), Kristin C. Mara, (unknown), Monica Hagan Vetter, Gretchen Glaser, Carrie Langstraat, Anita H. Chen, Martin A Martino, Tri A. Dinh, Ritu Salani, Isabel C. Green	2
8	Black and Hispanic women are less likely than white women to receive guideline-concordant endometrial cancer treatment 2020 ·American Journal of Obstetrics and Gynecology ·(unknown), (unknown), Allison Quick, (unknown), Ritu Salani, Ashley S. Felix	51
9	Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study 2020 ·International Journal of Gynecological Cancer ·Dana M. Chase, Helen Huang, Bradley J. Monk, Lois M. Ramondetta, Richard T. Penson, Karen M. Gil, Lisa M. Landrum, Mario M. Leitão, Ana Oaknin, Warner K. Huh, (unknown), Katina Robison, Saketh R. Guntupalli, Debra L. Richardson, Ritu Salani, Michael W. Sill, Lari Wenzel, Krishnansu S. Tewari	5
10	Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early-Stage Endometrial Cancer breakdown → 2019 ·Journal of Clinical Oncology ·Marcus E. Randall, Virginia L. Filiaci, D. Scott McMeekin, Vivian von Gruenigen, Helen Huang, Catheryn M. Yashar, Robert S. Mannel, Jae‐Weon Kim, Ritu Salani, Paul DiSilvestro, James J. Burke, Thomas Rutherford, Nick M. Spirtos, Keith Y. Terada, Penny R. Anderson, Wendy R. Brewster, William Small, Carol Aghajanian, David S. Miller	209
11	Time to chemotherapy in ovarian cancer: Compliance with ovarian cancer quality indicators at a National Cancer Institute-designated Comprehensive Cancer Center 2018 ·Gynecologic Oncology ·Adam C. ElNaggar, Erinn M. Hade, David M. O’Malley, Margaret Liang, Larry J. Copeland, Jeffrey M. Fowler, Ritu Salani, Floor Backes, David E. Cohn	12
12	Ovarian effects of radiation and cytotoxic chemotherapy damage 2018 ·Best Practice & Research Clinical Obstetrics & Gynaecology ·Casey Cosgrove, Ritu Salani	26
13	A Prospective, Comparative Study for the Evaluation of Postoperative Pain and Quality of Recovery in Patients Undergoing Robotic Versus Open Hysterectomy for Staging of Endometrial Cancer 2016 ·Journal of Minimally Invasive Gynecology ·David E. Cohn, (unknown), Laura Huffman, Ritu Salani, Jeffrey M. Fowler, Larry J. Copeland, David M. O’Malley, Floor Backes, Eric Eisenhauer, Mahmoud Abdel‐Rasoul, Erika Puente-Poushnejad, Sergio D. Bergese	18
14	Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline 2016 ·Obstetrical & Gynecological Survey ·Alexi A. Wright, Kari Bohlke, Deborah K. Armstrong, Michael A. Bookman, William A. Cliby, Robert L. Coleman, Don S. Dizon, Joseph J. Kash, Larissa A. Meyer, Kathleen N. Moore, Alexander Olawaiye, (unknown), Ritu Salani, Dee Sparacio, William P. Tew, Ignace Vergote, Mitchell I. Edelson	19
15	Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysis 2016 ·Gynecologic Oncology ·Kathleen N. Moore, James Java, (unknown), Peter G. Rose, Rachelle Lanciano, Paul DiSilvestro, J.T. Thigpen, Yi-Chun Lee, Krishnansu S. Tewari, Junzo Chino, Shelly Seward, David S. Miller, Ritu Salani, David H. Moore, Frederick B. Stehman	31
16	Long-Term Survival Advantage and Prognostic Factors Associated With Intraperitoneal Chemotherapy Treatment in Advanced Ovarian Cancer 2015 ·Obstetrical & Gynecological Survey ·Devansu Tewari, James Java, Ritu Salani, Deborah K. Armstrong, Maurie Markman, Thomas J. Herzog, Bradley J. Monk, John K. Chan	2
17	Predicting Inpatient Stay Lasting 2 Midnights or Longer After Robotic Surgery for Endometrial Cancer 2015 ·Journal of Minimally Invasive Gynecology ·Margaret Liang, (unknown), Kellie S. Rath, Erinn M. Hade, Aine Clements, Floor Backes, Eric Eisenhauer, Ritu Salani, David M. O’Malley, Jeffrey M. Fowler, David E. Cohn	7
18	Breast and gynecologic cancer-related extremity lymphedema: a review of diagnostic modalities and management options 2013 ·World Journal of Surgical Oncology ·Pankaj Tiwari, Michelle Coriddi, Ritu Salani, Stephen P. Povoski	70
19	Effect of chemotherapy delays and dose reductions on progression free and overall survival in the treatment of epithelial ovarian cancer 2011 ·Gynecologic Oncology ·Christa Nagel, Floor Backes, Erinn M. Hade, David E. Cohn, Eric Eisenhauer, David M. O’Malley, (unknown), Larry J. Copeland, Ritu Salani	38
20	Limited utility of conventional criteria for predicting unresectable disease in patients with advanced stage epithelial ovarian cancer 2008 ·Gynecologic Oncology ·Ritu Salani, Allison E. Axtell, M. Gerardi, Christine H. Holschneider, Robert E. Bristow	55

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact